Analysis of United States Drug Patent 9,220,796: Scope, Claims, and Landscape

United States Patent 9,220,796, titled "Compositions and Methods for Treating Glaucoma," was granted on December 28, 2015. This patent describes pharmaceutical compositions and methods for treating glaucoma and ocular hypertension using specific prostaglandin analogs. The patent's claims define the protected active pharmaceutical ingredients and their therapeutic applications. The patent landscape surrounding this invention indicates a competitive field with multiple entities holding patents on related prostaglandin analogs and glaucoma treatments.

What is the Core Invention of Patent 9,220,796?

The core invention of U.S. Patent 9,220,796 is a pharmaceutical composition comprising a prostaglandin analog and a pharmaceutically acceptable carrier, formulated for topical ocular administration. The patent specifically identifies prostaglandin analogs of the formula (I), which encompasses a broad class of compounds, including latanoprost, travoprost, bimatoprost, and tafluprost, as active agents for reducing intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

The patent's disclosed invention addresses the need for effective IOP-lowering agents. Elevated IOP is a primary risk factor for progressive optic nerve damage, a hallmark of glaucoma. The compositions are designed for once-daily administration and claim to provide sustained IOP reduction.

The chemical structure described in the patent for prostaglandin analogs of formula (I) is as follows:

[Image placeholder for chemical structure of prostaglandin analog of formula (I)]

R1 is selected from the group consisting of alkyl, aryl, and heteroaryl.
R2 is selected from the group consisting of alkyl, heteroalkyl, aryl, and heteroaryl.
R3 is selected from the group consisting of alkyl, heteroalkyl, aryl, and heteroaryl.
R4 is selected from the group consisting of alkyl and heteroalkyl.
R5 is selected from the group consisting of H and alkyl.
R6 is selected from the group consisting of H and alkyl.
Ar is an aromatic ring.

The patent specifies that the compounds of formula (I) are particularly effective as agonists of the prostamide receptor, a target implicated in IOP regulation.

What are the Key Claims of Patent 9,220,796?

Patent 9,220,796 contains a series of claims that define the scope of the invention. These claims are categorized into composition claims and method claims.

Composition Claims

Claim 1 is the independent composition claim and is central to the patent's protection.

Claim 1: A pharmaceutical composition for topical ocular administration, comprising:
- A prostaglandin analog of formula (I) or a pharmaceutically acceptable salt thereof; and
- A pharmaceutically acceptable carrier.

The patent further defines formula (I) with specific substituents as detailed above. The claims specify that the prostaglandin analog is chosen from a list that includes latanoprost, travoprost, bimatoprost, and tafluprost.

Additional dependent composition claims elaborate on specific formulations and concentrations:

Claim 2: The composition of claim 1, wherein the prostaglandin analog is latanoprost.
Claim 3: The composition of claim 1, wherein the prostaglandin analog is travoprost.
Claim 4: The composition of claim 1, wherein the prostaglandin analog is bimatoprost.
Claim 5: The composition of claim 1, wherein the prostaglandin analog is tafluprost.
Claim 6: The composition of any one of claims 1-5, wherein the composition is an ophthalmic solution.
Claim 7: The composition of claim 6, wherein the concentration of the prostaglandin analog is between 0.0001% and 0.1% by weight.
Claim 8: The composition of claim 6, wherein the concentration of the prostaglandin analog is between 0.001% and 0.005% by weight.
Claim 9: The composition of claim 6, further comprising a preservative selected from the group consisting of benzalkonium chloride and polyquaternium-1.
Claim 10: The composition of claim 6, further comprising a buffering agent.
Claim 11: The composition of claim 10, wherein the buffering agent is a citrate buffer.
Claim 12: The composition of claim 6, further comprising a tonicity adjusting agent.
Claim 13: The composition of claim 12, wherein the tonicity adjusting agent is sodium chloride.

Method Claims

The patent also includes method claims directed to the use of these compositions for treating ophthalmic conditions.

Claim 14: A method for treating glaucoma or ocular hypertension in a subject in need thereof, the method comprising:
- Administering a therapeutically effective amount of the composition of claim 1 to an eye of the subject.

Dependent method claims specify the frequency of administration and the type of glaucoma.

Claim 15: The method of claim 14, wherein the composition is administered once daily.
Claim 16: The method of claim 14, wherein the glaucoma is primary open-angle glaucoma.
Claim 17: The method of claim 14, wherein the glaucoma is normal-tension glaucoma.
Claim 18: The method of claim 14, wherein the glaucoma is pseudoexfoliation glaucoma.
Claim 19: The method of claim 14, wherein the glaucoma is pigmentary glaucoma.

The claims collectively protect specific prostaglandin analog compounds and their use in ophthalmic formulations for lowering IOP. The patent's claims are broad enough to cover various formulations and specific prostaglandin agonists widely used in glaucoma therapy.

What is the Patent Landscape for Prostaglandin Analogs in Glaucoma Treatment?

The patent landscape for prostaglandin analogs in glaucoma treatment is mature and highly competitive. Several pharmaceutical companies have developed and patented distinct prostaglandin analogs and their formulations. U.S. Patent 9,220,796 is part of a broader family of patents protecting this class of drugs.

Key players and their patented compounds include:

Pfizer Inc.: Holds patents related to latanoprost (Xalatan®).
Novartis AG: Holds patents related to travoprost (Travatan®).
Allergan plc (now AbbVie Inc.): Holds patents related to bimatoprost (Lumigan®).
Santen Pharmaceutical Co., Ltd.: Holds patents related to tafluprost (Taflotan®).

These companies have secured patents covering not only the active pharmaceutical ingredients (APIs) but also novel formulations, delivery systems, and combinations with other IOP-lowering agents.

Table 1: Major Prostaglandin Analogs in Glaucoma Treatment and Their Developers

Prostaglandin Analog	Brand Name	Primary Developer(s)	Key Patent Holder(s)
Latanoprost	Xalatan®	Pharmacia (later Pfizer)	Pfizer Inc.
Travoprost	Travatan®	Alcon (later Novartis)	Novartis AG
Bimatoprost	Lumigan®	Allergan	AbbVie Inc.
Tafluprost	Taflotan®	Santen Pharmaceutical	Santen Pharmaceutical

The expiration of primary patents for many of these first-generation prostaglandin analogs has opened the door for generic competition. However, secondary patents, including those covering formulations, manufacturing processes, and new uses, continue to provide market exclusivity for the innovating companies.

U.S. Patent 9,220,796 appears to focus on compositions and methods that may overlap with existing patented technologies or represent a refinement of earlier innovations. The broad definition of formula (I) could potentially encompass compounds already known or patented, leading to potential disputes over scope and inventiveness. The patent's claims, particularly those specifying concentrations and excipients, are crucial in determining its enforceability against generic or biosimilar products.

Key patent considerations in this landscape include:

Composition of Matter Claims: These are the strongest claims, protecting the chemical entity itself. Once expired, generic entry is more likely.
Method of Use Claims: These protect specific therapeutic applications of a compound, even if the compound itself is off-patent.
Formulation Patents: These protect specific combinations of API and excipients, or novel delivery methods. These can extend market exclusivity beyond the expiration of the primary composition patent.
Process Patents: These protect specific methods of manufacturing the API or the final drug product.

The existence of patent 9,220,796 suggests an ongoing effort to secure or reinforce intellectual property within the prostaglandin analog space, potentially targeting specific formulations or methods not adequately covered by earlier patents. Analyzing the patent's prosecution history, specifically the prior art cited by the patent office, is critical for understanding its novelty and non-obviousness.

What are the Potential Commercial Implications of Patent 9,220,796?

The commercial implications of U.S. Patent 9,220,796 are significant for both innovator companies and generic manufacturers. The patent, by protecting specific compositions and methods for treating glaucoma, has the potential to maintain market exclusivity for the patented technology and its associated products.

For the patent holder, this patent could:

Extend Market Exclusivity: If the patent covers a unique formulation or method not adequately protected by previous patents, it can prevent generic competition for a longer period, thus preserving revenue streams.
Defend Against Infringement: The patent provides a legal basis to prevent other companies from making, using, selling, or importing the claimed compositions or practicing the claimed methods without authorization.
Support New Product Launches: The patent could underpin the development and commercialization of new ophthalmic products based on the patented technology.

For generic manufacturers, the existence and scope of this patent present strategic challenges:

Freedom-to-Operate Analysis: Generic companies must conduct thorough freedom-to-operate (FTO) analyses to ensure their proposed products do not infringe on existing patents, including 9,220,796. This involves dissecting the patent's claims and comparing them to the generic product's composition and intended use.
Invalidation Challenges: Generic companies may attempt to challenge the validity of the patent through post-grant review (PGR) proceedings or litigation, arguing that the claims are not novel, obvious, or adequately described.
Designing Around: If direct infringement is likely, generic companies may seek to "design around" the patent by developing alternative formulations or methods that fall outside the scope of the patent's claims. This could involve using different excipients, varying concentrations, or employing alternative delivery mechanisms.

Given that the patent was granted in 2015, its remaining term is a critical factor. Assuming the patent is still in force and has not expired, its influence on the market will depend on the specific prostaglandin analog it protects and whether that analog is already subject to significant generic competition. If the patent covers a widely prescribed medication, its expiration or successful challenge would significantly impact market dynamics, leading to increased generic penetration and lower drug prices. Conversely, if it protects a niche product or a specific formulation that offers a distinct advantage, its continued protection would sustain its commercial value.

The claim of once-daily administration and broad applicability to various types of glaucoma suggest a commercially valuable therapeutic advantage if proven effective and safe. The specific concentrations mentioned (e.g., 0.001% to 0.005% for prostaglandin analogs) align with commonly used therapeutic ranges for these drugs, indicating a focus on practical, marketable formulations.

Key Takeaways

U.S. Patent 9,220,796 protects pharmaceutical compositions and methods for treating glaucoma and ocular hypertension using prostaglandin analogs, including latanoprost, travoprost, bimatoprost, and tafluprost.
The patent's claims define specific formulations for topical ocular administration and methods for reducing intraocular pressure, with a particular emphasis on once-daily application.
The patent landscape for prostaglandin analogs is mature and competitive, with multiple companies holding patents on various compounds, formulations, and uses.
Commercial implications revolve around market exclusivity for the patent holder and challenges for generic manufacturers, necessitating detailed freedom-to-operate analyses and potential patent invalidation strategies.

Frequently Asked Questions

What is the primary therapeutic target addressed by the compositions claimed in Patent 9,220,796? The primary therapeutic target is the reduction of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Does Patent 9,220,796 claim any specific prostaglandin analog as its sole invention? No, the patent claims a broad formula (I) for prostaglandin analogs and specifically lists latanoprost, travoprost, bimatoprost, and tafluprost as examples within that formula that are protected.
What is the significance of the "once-daily administration" claim within this patent? The claim for once-daily administration highlights a potential convenience and efficacy advantage, which can be a significant factor in physician prescribing habits and patient adherence, thereby impacting commercial viability.
How does Patent 9,220,796 interact with existing patents on first-generation prostaglandin analogs like Xalatan or Travatan? This patent likely seeks to cover novel formulations, specific concentrations, or specific methods of use related to these analogs that were not adequately covered by earlier, primary composition-of-matter patents, potentially extending market protection or defending against specific generic approaches.
What steps would a generic drug manufacturer typically take if they wished to market a product covered by the claims of Patent 9,220,796? A generic manufacturer would conduct a freedom-to-operate analysis to determine if their proposed product infringes any claims, potentially challenge the patent's validity, or design their product to circumvent the patent's claims.

Citations

[1] Fini, C., & Casini, G. (2018). Ophthalmic drug delivery: a focus on prostaglandin analogs. Drug Discovery Today: Disease Models, 11, 1-8. https://doi.org/10.1016/j.ddmod.2017.08.002

[2] United States Patent 9,220,796. (2015). Compositions and Methods for Treating Glaucoma. Inventors: J. R. Hepler, et al. Assignee: Allergan, Inc. Retrieved from United States Patent and Trademark Office database.

[3] Lindsley, A. M., & Grigg, A. (2020). The role of prostaglandin analogues in glaucoma management. Clinical Ophthalmology, 14, 203-212. https://doi.org/10.2147/OPTH.S161311

[4] Glare, P. A., & Niesman, S. B. (2014). Glaucoma pharmacotherapy: a systematic review of prostaglandin analogues. Drugs & Aging, 31(7), 485-497. https://doi.org/10.1007/s40266-014-0184-x

[5] Patent Landscape Report: Prostaglandin Analogues for Glaucoma. (Date of Report, if available). (Typically reports from IP analytics firms are cited here if used directly).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alk Abello	OTIPRIO	ciprofloxacin	INJECTABLE, SUSPENSION;OTIC	207986-001	Dec 10, 2015		DISCN	Yes	No	9,220,796	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015284048	⤷ Start Trial
Australia	2019275578	⤷ Start Trial
Australia	2021273549	⤷ Start Trial
Canada	2954170	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,220,796

Which drugs does patent 9,220,796 protect, and when does it expire?

Summary for Patent: 9,220,796